New strategies for Integrin Antagonism
The RGD binding integrins are involved in growth and metastasis of a number of cancers with significant unmet clinical need. Despite being the target of significant interest by the pharmaceutical industry, no effective integrin based anticancer agents have reached the clinic. We have developed a new integrin antagonist chemotype which can be applied to selective and polypharmacological antagonism or combination therapy involving integrin targeting.
Not yet patented. Studies to support filing a composition of matter patent are in progress.
To progress selected compounds through lead optimisation.
For more information contact Dr. Helen Sheldrake